Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 9;8(8):860.
doi: 10.3390/cells8080860.

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

Jacob J Adashek  1 , Rohit K Jain  2 , Jingsong Zhang  3
Affiliations
Review

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

Jacob J Adashek et al. Cells. .

Abstract

The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate cancer. There is an unmet need to develop novel therapies beyond targeting AR signaling for metastatic castration-resistant prostate cancer (mCRPC). Poly (ADP-ribose) polymerase inhibitors (PARPi) belong to a class of targeted agents being developed for the treatment of homologous recombination repair (HRR) deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in early phase trials as a monotherapy for HRR-deficient mCRPC. Among them, olaparib and rucaparib have breakthrough designations for BRCA1/2-mutated mCRPC. Phase II studies also reported clinical activity of the PARPi and abiraterone combination and the PARPi checkpoint inhibitor combination in HRR-intact mCRPC. Ongoing phase III trials are testing these combinations as frontline or later line treatments for mCRPC. This review summarizes the critical clinical data as well as ongoing clinical trials for developing PARPi in treating mCRPC.

Keywords: DNA damage repair deficiency; PARP inhibitors; prostate cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

J.J.A. and R.K.J. have no conflicts of interest. J.Z. receives consulting fees from AstraZeneca and ClovisOncology.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pritchard C.C., Mateo J., Walsh M.F., De Sarkar N., Abida W., Beltran H., Garofalo A., Gulati R., Carreira S., Eeles R., et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New Engl. J. Med. 2016;375:443–453. doi: 10.1056/NEJMoa1603144. - DOI - PMC - PubMed
    1. Shaheen M., Allen C., Nickoloff J.A., Hromas R. Synthetic lethality: Exploiting the addiction of cancer to DNA repair. Blood. 2011;117:6074–6082. - PubMed
    1. Murai J., Shar-yin N.H., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72:5588–5599. doi: 10.1158/0008-5472.CAN-12-2753. - DOI - PMC - PubMed
    1. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921. - PubMed
    1. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. doi: 10.1038/nature03443. - DOI - PubMed

MeSH terms

Substances